Your browser doesn't support javascript.
loading
Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
Huang, Qiu-Sha; Han, Tian-Xiao; Chen, Qi; Wu, Jin; Zhao, Peng; Wu, Ye-Jun; He, Yun; Zhu, Xiao-Lu; Fu, Hai-Xia; Wang, Feng-Rong; Zhang, Yuan-Yuan; Mo, Xiao-Dong; Han, Wei; Yan, Chen-Hua; Wang, Jing-Zhi; Chen, Huan; Chen, Yu-Hong; Han, Ting-Ting; Lv, Meng; Chen, Yao; Wang, Yu; Xu, Lan-Ping; Liu, Kai-Yan; Huang, Xiao-Jun; Zhang, Xiao-Hui.
Affiliation
  • Huang QS; Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • Han TX; National Clinical Research Center for Hematologic Disease, Beijing, China.
  • Chen Q; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Wu J; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
  • Zhao P; Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • Wu YJ; National Clinical Research Center for Hematologic Disease, Beijing, China.
  • He Y; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Zhu XL; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
  • Fu HX; Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • Wang FR; National Clinical Research Center for Hematologic Disease, Beijing, China.
  • Zhang YY; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Mo XD; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
  • Han W; Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • Yan CH; National Clinical Research Center for Hematologic Disease, Beijing, China.
  • Wang JZ; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Chen H; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
  • Chen YH; Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • Han TT; National Clinical Research Center for Hematologic Disease, Beijing, China.
  • Lv M; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Chen Y; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
  • Wang Y; Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • Xu LP; National Clinical Research Center for Hematologic Disease, Beijing, China.
  • Liu KY; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Huang XJ; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
  • Zhang XH; Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Bone Marrow Transplant ; 59(2): 239-246, 2024 02.
Article in En | MEDLINE | ID: mdl-38012449
ABSTRACT
Bronchiolitis obliterans syndrome (BOS) is a common and potentially devastating noninfectious pulmonary complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, predictive tools for BOS are not available. We aimed to identify the clinical risk factors and establish a prognostic model for BOS in patients who undergo allo-HSCT. We retrospectively identified a cohort comprising 195 BOS patients from 6100 consecutive patients who were allografted between 2008 and 2022. The entire cohort was divided into a derivation cohort and a validation cohort based on the time of transplantation. Via multivariable Cox regression methods, declining forced expiratory volume at 1 s (FEV1) to <40%, pneumonia, cGVHD except lung, and respiratory failure were found to be independent risk factors for the 3-year mortality of BOS. A risk score called FACT was constructed based on the regression coefficients. The FACT model had an AUC of 0.863 (95% CI 0.797-0.928) in internal validation and 0.749 (95% CI 0.621-0.876) in external validation. The calibration curves showed good agreement between the FACT-predicted probabilities and actual observations. The FACT risk score will help to identify patients at high risk and facilitate future research on developing novel, effective interventions to personalize treatment.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bronchiolitis Obliterans / Hematopoietic Stem Cell Transplantation / Bronchiolitis Obliterans Syndrome Limits: Humans Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bronchiolitis Obliterans / Hematopoietic Stem Cell Transplantation / Bronchiolitis Obliterans Syndrome Limits: Humans Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2024 Document type: Article Affiliation country:
...